Novartis Pharmaceuticals Corporation has issued a nationwide recall for certain heart failure and high blood pressure medications due to potency issues, as announced by the FDA.

Swiss drugmaker Novartis's stock chart indicates a potential bullish reversal, according to analyst Cappelleri, following its recent earnings report where it held near recent highs.

Greek Health Minister Adonis Georgiadis launched a strong attack against SYRIZA regarding the Novartis case, dismissing their reintroduction of the issue as 'reheated food' and criticizing Marios Salmas.

Marios Salmas announced he is filing a lawsuit against Adonis Georgiadis, accusing him of presenting "forged and visibly adulterated documents" and reiterating his demand to reopen the Novartis case file.

Pavlos Marinakis, a Greek government spokesperson, stated that the 'embankment' theory aiming to cover up the train crash has collapsed and is not being investigated by the judiciary. He also clarified that Health Minister Adonis Georgiadis remains in his position, rejecting calls to reopen the Novartis case.

An analysis suggests that while Big Pharma companies are acquiring growth, Novartis is strategically betting on its internal drug development pipeline for future expansion.

The Greek Parliament voted to lift the parliamentary immunity of Zoe Konstantopoulou with 160 votes in favor. Konstantopoulou stated that she believes there is an order to target her but affirmed her continued presence and activity.

Pharmaceutical giant Novartis is back on a growth trajectory, skillfully rejuvenating its business despite significant losses from its off-patent heart medication Entresto. The company is expected to face a more turbulent second half of the year on the stock market.

Novartis reported a return to sales growth in its second quarter, as the performance of newer medicines successfully offset pressure from generic competition.

Pharmaceutical giant Novartis is under pressure to prove the strength of its drug pipeline as its valuation premium comes under investor focus.

American pharmaceutical giant Eli Lilly is projected to reach nearly $140 billion in revenue by 2032, largely driven by its weight-loss medications. The company's stock market valuation has nearly doubled that of Roche and Novartis combined.

Several pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Novartis, are being highlighted as leading investment opportunities in the longevity and anti-aging sector. These companies are recognized for their potential in developing treatments and technologies aimed at extending lifespan and combating aging.

Investors are advised to watch four specific stocks, AMD, Honeywell, Western Digital, and Novartis, on Friday due to various market factors.

North Carolina has successfully attracted significant investments from healthcare companies like Roche, Novartis, and Ypsomed, and the state's governor is actively promoting further growth in the sector.

Novartis has acquired Avidity Biosciences as part of a larger spending spree by the pharmaceutical giant. This acquisition is one of several strategic moves by Novartis to expand its portfolio.

Novartis AG (NVS) is expanding its manufacturing presence in the United States by establishing a new site in Texas.

Germany wants to save billions with larger price reductions on medicines. Meanwhile, the pharmaceutical company has to allay investors' concerns about patent expiries.

Novartis reported first-quarter earnings that fell short of sales and profit estimates, primarily due to the impact of generic competition on its drug Entresto. Despite the miss, the company reaffirmed its growth outlook for 2026.

Novartis, Amgen, and Eli Lilly are investing in research to target a specific, lesser-known type of cholesterol, hoping it will lead to the next generation of blockbuster heart medications.

An article compares Novartis and Merck to determine which pharmaceutical company offers a better dividend stock option for investors.

AI research company Anthropic has announced the addition of the CEO of pharmaceutical giant Novartis to its board of directors, signaling a potential expansion of its strategic oversight.

Novartis has confirmed its intention to acquire Excellergy, an allergy-drug developer, in a deal valued at up to $2 billion, with the Wall Street Journal providing further details and confirmation on the acquisition.

This week's notable healthcare headlines focus on key developments concerning pharmaceutical companies such as Eli Lilly, Novo Nordisk, and Novartis.

Novartis to boost multidimensional investments  China Daily

Novartis is offering high-grade debt to secure funding for its recently announced $12 billion acquisition deal with Avidity.

Die Rechtsunsicherheit unter Donald Trump sorgte 2025 für einen Lobbying-Boom. Auch Konzerne aus der Schweiz haben ihr Budget zum Teil deutlich aufgestockt, um in den USA gehört zu werden.

Novartis And Henrietta Lacks’ Family Reach A Settlement  Forbes

Avidity (RNA) has changed the date for its shareholder vote concerning the proposed merger with Novartis.

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine

Novartis announced plans to construct a new radioligand therapy manufacturing facility in Texas, aiming to expand its US production capabilities.

Novartis celebrates double recognition for clinical research excellence in Saudi Arabia  Arab News

Madrigal Pharmaceuticals experienced a stock sell-off, while a former Novartis executive moved to Daiichi.

Analysts are offering their projections on the future direction and performance of Novartis AG (NVS).

Novartis has received approval in the United Kingdom for its drug Rhapsido, indicated for the treatment of urticaria, commonly known as hives.

Five major scandals—Novartis, OPEKEPE, wiretapping, Tempi, and Recycling Houses—are reportedly shaking the Maximos Mansion, making the scenario of early elections prohibitive for the Greek government.

A new dispute has erupted between Adonis Georgiadis and Marios Salmas concerning the Novartis case, with Georgiadis accusing Salmas of rehashing conspiracy claims and Salmas threatening legal action.

SYRIZA's Political Secretariat announced its readiness for upcoming elections, focusing on candidate lists and highlighting the Novartis scandal. The party aims to change the political landscape through these efforts.

P. Marinakis commented on independent MP Marios Salmas's allegations against Adonis Georgiadis, suggesting they are an attempt to reopen the Novartis case through indirect means.

Following new revelations from Salmas, there are calls for the Greek justice system to reopen the Novartis case. The article also mentions concerns about the concession of Kalamata airport impacting local development and transparency.

The Novartis case file has been reopened in Greece, with the Health Minister facing scrutiny as evidence of his involvement in the high-profile affair is reportedly included in parliamentary records.

Several companies, including Charles Schwab, MSCI, Wintrust Financial, and General Motors, have released their Q2 earnings reports. While some companies like Charles Schwab beat earnings expectations, others faced disappointments, such as higher expenses.

Both 3M and Novartis have reported strong financial results for the second quarter, surpassing top and bottom-line estimates. Following these positive outcomes, both companies have reaffirmed their financial outlooks for 2026.

An earnings preview for Novartis examines whether new medicines can offset the impact of generic drug pressure and growing U.S. pricing risks on the company's financial performance.

Novartis has secured full FDA approval for its kidney disease drug Fabhalta, specifically for the treatment of IgA nephropathy.

Novartis's gene therapy, Itvisma, has received approval for use in the European Union to treat spinal muscular atrophy, marking a significant development for patients with the condition.

Novartis and Antares have announced a collaboration to develop cancer drugs, with the deal potentially valued at up to $1.9 billion.

More biotech firms are likely to change hands this year than ever before. Many pharmaceutical groups urgently need new products. Roche and Novartis are also on a shopping spree.

Novartis's therapy for a muscle disease has successfully completed an early-stage study, indicating potential progress in treatment development.

Novartis (NVS) has announced new data regarding its drug Cosentyx® in the treatment of Polymyalgia Rheumatica.

Generics drugmaker Sandoz, a Novartis spin-off, has urged the EU to investigate alleged dumping practices by China, claiming that Chinese overcapacity threatens European self-reliance and access to key antibiotics.

Pharmaceutical giant Novartis has commenced construction on its new Radioligand Therapy (RLT) manufacturing facility in Texas, United States. The center is expected to boost the company's production capabilities for advanced cancer treatments.

Swiss pharmaceutical company Novartis has announced plans to build its seventh manufacturing facility in the United States, expanding its production capabilities.

Pharmaceutical giant Novartis is experiencing pressure from the rise of copycat drugs, impacting its market share and financial performance.

Novartis has secured approval from the European Commission for its new drug, Rhapsido, intended for the treatment of skin diseases.

The Chief Executive Officer of Novartis has joined the board of directors for the artificial intelligence company Anthropic.

Barcelona has emerged as a major European hub for the pharmaceutical industry, with Novartis establishing innovation centers that integrate knowledge, technology, and innovation. These hubs are reimagining medicine and translating their findings to the global market, positioning Spain as a global talent laboratory for the company.

This article highlights notable healthcare headlines for the week, focusing on developments related to companies such as Merck, Medtronic, and Novartis.

Novartis has publicly announced plans for additional investment in China, signaling its continued commitment to the market.

Several major corporate deals involving companies such as Ecolab, Novartis, and 3M have been highlighted this week in financial news.

Seiner Grossmutter wurden, ohne ihre Zustimmung, Tumorproben entnommen. Heute klagt Michael jene Pharmafirmen an, die damit forschen. Mit Novartis kam er jetzt zu einer Einigung.

Novartis, Nucor, and US Forged Rings are among several companies expanding their domestic investments, signaling a trend towards increased local economic activity and manufacturing.

Novartis has announced plans to establish a new manufacturing facility for radioligand therapy in Denton, Texas, expanding its production capabilities.

The family of Henrietta Lacks has reached a settlement with pharmaceutical company Novartis regarding the unauthorized use of her cells, which were taken without her consent in 1951.

Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy, alleging illegal importation of a Canadian version of their allergy medicine.

Novartis announced plans to construct a new radioligand therapy manufacturing facility in Texas, aiming to expand its production capabilities within the United States.

An analysis suggests that pharmaceutical giant Novartis could be a stable, long-term core holding for investors.

Novartis has entered into a licensing agreement potentially worth up to $1.8 billion for oral peptide drugs.

Pharmaceutical company Novartis has announced that its cancer drug, Pluvicto, has received an expanded indication, allowing it to be used for a broader patient population or condition.

SYRIZA (Koumoundourou) has called for the re-examination of the Novartis case files, specifically mentioning those related to Georgiadis and Avramopoulos, with former minister Pavlos Polakis claiming vindication for his stance on the scandal.

SYRIZA-P.S. has outlined its election menu and "6 actions" regarding the Novartis case, aiming to move past internal ambiguity and achieve a unified strategy to shift the political landscape in favor of the modern Left.

Adonis Georgiadis publicly accused former minister Marios Salmas of initiating the Novartis scandal conspiracy, claiming Salmas sought whistleblower compensation but was rejected by American authorities.

Health Minister Adonis Georgiadis responded extensively to what Marios Salmas stated in Parliament regarding the Novartis case. He emphasized that what Mr. Salmas allegedly revealed.

Greek politicians are engaged in a fierce debate following new allegations in the Novartis case, with calls for Minister Adonis Georgiadis's resignation. PASOK has demanded a clear statement from Georgiadis, warning that resignation is the only option if he fails to address the accusations without evasion.

Victoria Tian, head of Novartis Poland, emphasizes that investing in solutions for health and independence yields benefits far beyond the healthcare system itself.

Several companies, including Coinbase, Micron, Nebius, Hasbro, Utz Brands, General Motors, 3M, and Novartis, experienced notable stock movements during premarket and midday trading sessions.

Novartis reported a recovery in its second-quarter profits, with revenue growth now primarily driven by its newer pharmaceutical products.

Novartis's future growth prospects are heavily reliant on the success of its drug pipeline, which is currently facing a critical evaluation as upcoming trial results are anticipated.

An analysis compares Novartis and Teva to determine which pharmaceutical stock presents a better investment opportunity for 2026.

The Novartis factory in Ljubljana is set to create 300 new job opportunities for specialists. This expansion signifies a significant investment and growth for the pharmaceutical company in the region.

Novartis AG (NVS) announced that its experimental drug for a rare muscle disease has shown encouraging results in early-stage clinical trials.

Kostas Papagiannis, President and CEO of Novartis Greece, Cyprus, and Malta, highlighted the critical importance of strategically utilizing health data, emphasizing that unexploited data represents a lost opportunity for patients and incurs costs when not systematically used in decision-making.

Shares of Kymera and Monte Rosa Therapeutics saw gains after Novartis announced a deal for molecular glue drugs, impacting the pharmaceutical sector.

An experimental radiopharmaceutical drug developed by Novartis has demonstrated promising results in an early-stage study, indicating potential for future medical applications.

Novartis has announced plans to increase its multidimensional investments, signaling strategic growth and expansion initiatives.

Novartis reported a miss on its first-quarter sales, which analysts suggest indicates a broader industry trend towards utilizing mergers and acquisitions as a remedy for financial performance.

Pharmaceutical giant Novartis is experiencing increased pressure from generic, copycat drugs. This competition is impacting the company's market share and profitability.

An analysis suggests Novartis AG is one of the best low-risk, high-growth investment opportunities currently available on the market.

The World Health Organization has prequalified Novartis' Coartem Baby, an antimalarial drug, for use in infants, marking a significant step in combating malaria in young children.

Novartis is broadening its global community health initiatives, with an ambitious goal to reach more than 30 countries by the year 2030. This expansion aims to improve health outcomes in various communities worldwide.

Pharmaceutical company Novartis has charted a significant expansion plan, signaling strategic growth and increased investment in its operations.

Pharmaceutical giant Novartis has announced its intention to purchase Excellergy, a developer of allergy drugs, in a deal valued at up to $2 billion, expanding its portfolio in the allergy treatment market.

This week's notable healthcare headlines focus on key developments concerning pharmaceutical companies such as Eli Lilly, which is expanding Zepbound access, along with Novo Nordisk and Novartis.

Pharmaceutical giant Novartis is reportedly set to acquire an experimental breast cancer drug in a deal valued at up to $3 billion, expanding its oncology pipeline.

Als Teil eines ausergewöhnlichen Pharma-Powerpaars sorgte sie für Aufsehen. Nun verlässt Srishti Gupta, die Ehefrau von Novartis-CEO Narasimhan, überraschend Idorsia.

Pharmaceutical company Novartis has unveiled a new share buyback program, signaling a move to return capital to shareholders.

Novartis has opened a new factory in Mengeš, Slovenia, which will initially produce active ingredients for breast cancer and rare blood disease medications, marking a significant milestone for the company.

Novartis is the second drug company to settle a lawsuit brought by the family of a woman whose cells have enabled huge advances in science.

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine

Aurobindo Pharma's subsidiary has received approval from the U.S. FDA for its generic version of a Novartis drug, marking a significant development for the company.

An article explores the potential of Novartis stock as a component for building a millionaire retirement portfolio.

An analysis of ship movements reveals that the Trump administration is isolating Cuba, leading to a vulnerable moment for the island nation.

Forlesia Cook, a grandmother who lost her grandson to gun violence, urged voters to prioritize causes over party loyalty in America while defending President Trump at a Black History Month event.